4//SEC Filing
BAUER EUGENE A 4
Accession 0001192482-20-000117
CIK 0001138776other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:18 PM ET
Size
21.1 KB
Accession
0001192482-20-000117
Insider Transaction Report
Form 4
BAUER EUGENE A
DirectorExecutive Chairman
Transactions
- Disposition to Issuer
Warrant (Right to Buy)
2020-02-03−3,530→ 0 totalExercise: $2.84Exp: 2022-10-17→ Common Stock (3,530 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−50,000→ 0 totalExercise: $1.55Exp: 2028-04-17→ Common Stock (50,000 underlying) - Disposition to Issuer
Common Stock
2020-02-03−165,715→ 0 total - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−28,571→ 0 totalExercise: $8.19Exp: 2020-09-14→ Common Stock (28,571 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−50,000→ 0 totalExercise: $6.70Exp: 2023-11-11→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−20,000→ 0 totalExercise: $7.01Exp: 2025-02-18→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−20,000→ 0 totalExercise: $4.83Exp: 2026-04-15→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−20,000→ 0 totalExercise: $1.32Exp: 2027-06-22→ Common Stock (20,000 underlying)
Footnotes (8)
- [F1]Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock.
- [F2]This option, which became exercisable on Septmeber 14, 2011, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F3]This option, which became exercisable on November 11, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F4]This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F5]This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F6]This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F7]This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F8]This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void.
Documents
Issuer
Aevi Genomic Medicine, Inc.
CIK 0001138776
Entity typeother
Related Parties
1- filerCIK 0001210524
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 4:18 PM ET
- Size
- 21.1 KB